tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

TVTX Stock Latest News

Travere Therapeutics price target raised to $23 from $20 at JPMorgan
The FlyTravere Therapeutics price target raised to $23 from $20 at JPMorgan
7d ago
TVTX
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PremiumPress Releases
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
7d ago
TVTX
Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference
PremiumPress Releases
Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference
9d ago
TVTX
Travere Therapeutics price target raised to $23 from $18 at Canaccord
PremiumThe Fly
Travere Therapeutics price target raised to $23 from $18 at Canaccord
10d ago
TVTX
Travere upgraded to Buy at Guggenheim after IgAN approval, ahead of FSGS updates
PremiumThe Fly
Travere upgraded to Buy at Guggenheim after IgAN approval, ahead of FSGS updates
11d ago
TVTX
Travere Therapeutics upgraded to Buy from Neutral at Guggenheim
PremiumThe FlyTravere Therapeutics upgraded to Buy from Neutral at Guggenheim
11d ago
TVTX
Broadcom AI results fail to enthuse the Street: Morning Buzz
Premium
The Fly
Broadcom AI results fail to enthuse the Street: Morning Buzz
13d ago
X
BE
Travere Therapeutics price target raised to $23 from $14 at Citi
Premium
The Fly
Travere Therapeutics price target raised to $23 from $14 at Citi
13d ago
TVTX
Ligand, Travere Therapeutics receives full FDA approval for Filspari
PremiumThe Fly
Ligand, Travere Therapeutics receives full FDA approval for Filspari
13d ago
LGND
TVTX
Travere Therapeutics price target raised to $19 from $18 at BofA
PremiumThe Fly
Travere Therapeutics price target raised to $19 from $18 at BofA
14d ago
TVTX
Travere Therapeutics price target raised to $23 from $20 at H.C. Wainwright
PremiumThe Fly
Travere Therapeutics price target raised to $23 from $20 at H.C. Wainwright
14d ago
TVTX
Travere Therapeutics trading resumes
PremiumThe Fly
Travere Therapeutics trading resumes
14d ago
TVTX
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
PremiumPress ReleasesTravere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
14d ago
TVTX
Travere Therapeutics’ Filspari in kidney function granted full approval by FDA
Premium
The Fly
Travere Therapeutics’ Filspari in kidney function granted full approval by FDA
14d ago
TVTX
Travere Therapeutics trading halted, news pending
Premium
The Fly
Travere Therapeutics trading halted, news pending
14d ago
TVTX
Evercore says Filspari inclusion in new guidelines should give Travere boost
PremiumThe Fly
Evercore says Filspari inclusion in new guidelines should give Travere boost
20d ago
TVTX
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024
PremiumPress Releases
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024
28d ago
TVTX
Travere Therapeutics price target raised to $20 from $19 at JPMorgan
PremiumThe Fly
Travere Therapeutics price target raised to $20 from $19 at JPMorgan
1M ago
TVTX
Travere Therapeutics to Present at Upcoming Investor Conferences
PremiumPress Releases
Travere Therapeutics to Present at Upcoming Investor Conferences
1M ago
TVTX
Travere Therapeutics price target raised to $20 from $19 at H.C. Wainwright
PremiumThe FlyTravere Therapeutics price target raised to $20 from $19 at H.C. Wainwright
2M ago
TVTX
Travere Therapeutics price target raised to $14 from $12 at Barclays
Premium
The Fly
Travere Therapeutics price target raised to $14 from $12 at Barclays
2M ago
TVTX
Travere Therapeutics files automatic mixed securities shelf
Premium
The Fly
Travere Therapeutics files automatic mixed securities shelf
2M ago
TVTX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >